- Home
- RNXT
RNXT
RenovoRx Inc.
as 01-17-2025 4:00pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 33.8M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 101.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $1.86 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025
Business Wire
19 days ago
RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform
GlobeNewswire
a month ago
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer
GlobeNewswire
a month ago
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET
Medical Device Network
a month ago
RenovoRx begins commercialisation of RenovoCath device
GlobeNewswire
a month ago
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System
MT Newswires
2 months ago
RenovoRx Says Northwell Health Cancer Institute Begins Enrolling Patients for Phase III Pancreatic Cancer Trial
GlobeNewswire
2 months ago
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.